Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Non-Current Liabilities (2022 - 2024)

Historic Total Non-Current Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Q2 2024 value amounting to $166.8 million.

  • Rhythm Pharmaceuticals' Total Non-Current Liabilities rose 3199.12% to $166.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $166.8 million, marking a year-over-year increase of 3199.12%. This contributed to the annual value of $161.8 million for FY2023, which is 3846.46% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Total Non-Current Liabilities of $166.8 million as of Q2 2024, which was up 3199.12% from $162.5 million recorded in Q1 2024.
  • Rhythm Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $166.8 million for Q2 2024, and its period low was $80.5 million during Q2 2022.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $126.3 million (2023), whereas its average is $133.7 million.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Total Non-Current Liabilities soared by 5702.55% in 2023 and then surged by 2903.41% in 2024.
  • Rhythm Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $116.9 million in 2022, then skyrocketed by 38.46% to $161.8 million in 2023, then increased by 3.04% to $166.8 million in 2024.
  • Its last three reported values are $166.8 million in Q2 2024, $162.5 million for Q1 2024, and $161.8 million during Q4 2023.